{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:44:05Z","timestamp":1773524645894,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA076167"],"award-info":[{"award-number":["CA076167"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Resistance to molecular therapies frequently occur due to genetic changes affecting the targeted pathway. In myeloid and lymphoid leukemias\/lymphomas resulting from constitutive activation of FGFR1 kinases, resistance has been shown to be due either to mutations in FGFR1 or deletions of PTEN. RNA-Seq analysis of the resistant clones demonstrates expression changes in cell death pathways centering on the p53 upregulated modulator of apoptosis (Puma) protein. Treatment with different tyrosine kinase inhibitors (TKIs) revealed that, in both FGFR1 mutation and Pten deletion-mediated resistance, sustained Akt activation in resistant cells leads to compromised Puma activation, resulting in suppression of TKI-induced apoptosis. This suppression of Puma is achieved as a result of sequestration of inactivated p-Foxo3a in the cytoplasm. CRISPR\/Cas9 mediated knockout of Puma in leukemic cells led to an increased drug resistance in the knockout cells demonstrating a direct role in TKI resistance. Since Puma promotes cell death by targeting Bcl2, TKI-resistant cells showed high Bcl2 levels and targeting Bcl2 with Venetoclax (ABT199) led to increased apoptosis in these cells. In vivo treatment of mice xenografted with resistant cells using ABT199 suppressed leukemogenesis and led to prolonged survival. This in-depth survey of the underlying genetic mechanisms of resistance has identified a potential means of treating FGFR1-driven malignancies that are resistant to FGFR1 inhibitors.<\/jats:p>","DOI":"10.1038\/s41419-020-03098-1","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T16:03:07Z","timestamp":1603209787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia\/lymphoma syndrome"],"prefix":"10.1038","volume":"11","author":[{"given":"Yun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baohuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yating","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hualei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chesley-Anne","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingqiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"Cowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-9211","authenticated-orcid":false,"given":"Tianxiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"3098_CR1","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1172\/JCI76094","volume":"125","author":"S Gross","year":"2015","unstructured":"Gross, S., Rahal, R., Stransky, N., Lengauer, C. & Hoeflich, K. P. Targeting cancer with kinase inhibitors. J. Clin. Invest. 125, 1780 (2015).","journal-title":"J. Clin. Invest."},{"key":"3098_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/bs.acr.2018.02.003","volume":"138","author":"SA Rosenzweig","year":"2018","unstructured":"Rosenzweig, S. A. Acquired resistance to drugs targeting tyrosine kinases. Adv. Cancer Res. 138, 71 (2018).","journal-title":"Adv. Cancer Res."},{"key":"3098_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","volume":"41","author":"CC Jackson","year":"2010","unstructured":"Jackson, C. C., Medeiros, L. J. & Miranda, R. N. 8p11 myeloproliferative syndrome: a review. Hum. Pathol. 41, 461 (2010).","journal-title":"Hum. Pathol."},{"key":"3098_CR4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/bjh.13877","volume":"175","author":"JK Cowell","year":"2016","unstructured":"Cowell, J. K., Qin, H., Chang, C. S., Kitamura, E. & Ren, M. A model of BCR-FGFR1 driven human AML in immunocompromised mice. Br. J. Haematol. 175, 542 (2016).","journal-title":"Br. J. Haematol."},{"key":"3098_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/leu.2015.136","volume":"30","author":"MS Khodadoust","year":"2016","unstructured":"Khodadoust, M. S. et al. Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia 30, 947 (2016).","journal-title":"Leukemia"},{"key":"3098_CR6","doi-asserted-by":"publisher","first-page":"49733","DOI":"10.18632\/oncotarget.10438","volume":"7","author":"Q Wu","year":"2016","unstructured":"Wu, Q. et al. Targeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models. Oncotarget 7, 49733 (2016).","journal-title":"Oncotarget"},{"key":"3098_CR7","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/ijc.30848","volume":"141","author":"JK Cowell","year":"2017","unstructured":"Cowell, J. K. et al. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia\/lymphomas. Int. J. Cancer 141, 1822 (2017).","journal-title":"Int. J. Cancer"},{"key":"3098_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038265","volume":"7","author":"M Ren","year":"2012","unstructured":"Ren, M., Tidwell, J. A., Sharma, S. & Cowell, J. K. Acute progression of BCR-FGFR1 induced murine B-lympho\/myeloproliferative disorder suggests involvement of lineages at the pro-B Cell Stage. PLoS ONE 7, e38265 (2012).","journal-title":"PLoS ONE"},{"key":"3098_CR9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1182\/blood-2009-03-212704","volume":"11","author":"M Ren","year":"2009","unstructured":"Ren, M., Li, X. & Cowell, J. K. Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-FGFR1 chimeric tyrosine kinase. Blood 11, 1576 (2009).","journal-title":"Blood"},{"key":"3098_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2013-03-489823","volume":"122","author":"M Ren","year":"2013","unstructured":"Ren, M., Qin, H., Kitamura, E. & Cowell, J. K. Disregulation of multiple signaling pathways in the development of myeloid and lymphoid malignancies associated with the CNTRL-FGFR1 fusion kinase in human and mouse models. Blood 122, 1007 (2013).","journal-title":"Blood"},{"key":"3098_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood.V68.5.1101.1101","volume":"68","author":"AJ Furley","year":"1986","unstructured":"Furley, A. J. et al. Divergent molecular phenotypes of KG1 and KG1a myeloid cell lines. Blood 68, 1101 (1986).","journal-title":"Blood"},{"key":"3098_CR12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.137695","volume":"101","author":"H Qin","year":"2016","unstructured":"Qin, H., Wu, Q., Cowell, J. K. & Ren, M. FGFR1OP2-FGFR1 induced myeloid leukemia and T-cell lymphoma in a mouse model. Haematologica 101, e91 (2016).","journal-title":"Haematologica"},{"key":"3098_CR13","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/1947601911407325","volume":"1","author":"M-M Georgescu","year":"2010","unstructured":"Georgescu, M.-M. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 1, 1170 (2010).","journal-title":"Genes Cancer"},{"key":"3098_CR14","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1084\/jem.20060353","volume":"203","author":"H You","year":"2006","unstructured":"You, H. et al. FOXO3a-dependent regulation of Puma in response to cytokine\/growth factor withdrawal. J. Exp. Med. 203, 1657 (2006).","journal-title":"J. Exp. Med."},{"key":"3098_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202 (2013).","journal-title":"Nat. Med."},{"key":"3098_CR16","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs, S. et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 124, 3738 (2014).","journal-title":"Blood"},{"key":"3098_CR17","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/onc.2009.451","volume":"29","author":"W Qiu","year":"2010","unstructured":"Qiu, W., Leibowitz, B., Zhang, L. & Yu, J. Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K\/AKT\/p53 axis. Oncogene 29, 1622 (2010).","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"3098_CR18","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1038\/onc.2009.45","volume":"27","author":"J Yu","year":"2008","unstructured":"Yu, J. & Zhang, L. PUMA, a potent killer with or without p53. Oncogene 27(Suppl 1), S71 (2008).","journal-title":"Oncogene"},{"key":"3098_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1535-6108(03)00244-7","volume":"4","author":"JR Jeffers","year":"2003","unstructured":"Jeffers, J. R. et al. PUMA is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4, 321 (2003).","journal-title":"Cancer Cell"},{"key":"3098_CR20","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1038\/s41375-018-0124-y","volume":"32","author":"T Hu","year":"2018","unstructured":"Hu, T. et al. FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia\/lymphoma syndrome. Leukemia 32, 2363 (2018).","journal-title":"Leukemia"},{"key":"3098_CR21","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1158\/1535-7163.MCT-10-0635","volume":"9","author":"C Dudgeon","year":"2010","unstructured":"Dudgeon, C. et al. PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01. Mol. Cancer Ther. 9, 2893 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"3098_CR22","first-page":"ra20","volume":"36","author":"GR Bean","year":"2013","unstructured":"Bean, G. R. et al. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci. Signal. 36, ra20 (2013).","journal-title":"Sci. Signal."},{"key":"3098_CR23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/cdd.2011.136","volume":"19","author":"SP Garrison","year":"2012","unstructured":"Garrison, S. P. et al. Genetically defining the mechanism of PUMA- and Bim-induced apoptosis. Cell Death Differ. 19, 642 (2012).","journal-title":"Cell Death Differ."},{"key":"3098_CR24","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1084\/jem.20061552","volume":"203","author":"M Erlacher","year":"2006","unstructured":"Erlacher, M. et al. PUMA cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J. Exp. Med. 203, 2939 (2006).","journal-title":"J. Exp. Med."},{"key":"3098_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cgt.2012.84","volume":"20","author":"L-N Zhang","year":"2013","unstructured":"Zhang, L.-N., Li, J.-Y. & Xu, W. A review of the role of PUMA, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Ther. 20, 1 (2013).","journal-title":"Cancer Gene Ther."},{"key":"3098_CR26","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S0960-9822(00)00728-4","volume":"10","author":"PF Dijkers","year":"2000","unstructured":"Dijkers, P. F., Medema, R. H., Lammers, J. W., Koenderman, L. & Coffer, P. J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 10, 1201 (2000).","journal-title":"Curr. Biol."},{"key":"3098_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/leu.2012.188","volume":"27","author":"M Ren","year":"2013","unstructured":"Ren, M., Qin, H., Ren, R. & Cowell, J. K. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia 27, 32 (2013).","journal-title":"Leukemia"},{"key":"3098_CR28","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1093\/annonc\/mdy173","volume":"29","author":"S Verstovsek","year":"2018","unstructured":"Verstovsek, S. et al. Treatment of the myeloid\/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. Ann. Oncol. 29, 1880 (2018).","journal-title":"Ann. Oncol."},{"key":"3098_CR29","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson, M. A. et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 127, 3215 (2016).","journal-title":"Blood"},{"key":"3098_CR30","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1158\/1078-0432.CCR-16-0955","volume":"23","author":"AW Roberts","year":"2017","unstructured":"Roberts, A. W., Stilgenbauer, S., Seymour, J. F. & Huang, D. C. S. Venetoclax in patients with previously treated chronic lymphocytic leukemia. Clin. Cancer Res. 23, 4527 (2017).","journal-title":"Clin. Cancer Res."},{"key":"3098_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3098_CR32","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/leu.2017.32","volume":"31","author":"J Deng","year":"2017","unstructured":"Deng, J. et al. Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia 31, 2075 (2017).","journal-title":"Leukemia"},{"key":"3098_CR33","doi-asserted-by":"publisher","first-page":"6837","DOI":"10.1182\/blood-2010-07-295725","volume":"117","author":"M Ren","year":"2011","unstructured":"Ren, M. & Cowell, J. K. Constitutive activation of the Notch pathway in ZNF198-FGFR1-induced T-cell lymphomas provides a novel therapeutic target for this atypical myeloproliferative disease. Blood 117, 6837 (2011).","journal-title":"Blood"},{"key":"3098_CR34","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1101\/gr.229102","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12, 996 (2002).","journal-title":"Genome Res."},{"key":"3098_CR35","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1093\/nar\/gkw1195","volume":"45","author":"T Hu","year":"2017","unstructured":"Hu, T. et al. Long non-coding RNAs transcribed by ERV-9 LTR retrotransposon act in cis to modulate long-range LTR enhancer function. Nucleic Acids Res. 45, 4479 (2017).","journal-title":"Nucleic Acids Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03098-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03098-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03098-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:30:45Z","timestamp":1670254245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03098-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["3098"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-03098-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"19 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"884"}}